Mr. Ranan Dasgupta

Mr. Ranan Dasgupta
After graduation from Cambridge University, he underwent surgical training in London, including a higher degree MD thesis in neuro-urology from UCL. Appointed at Imperial College Healthcare as a Consultant Endourological Surgeon, he has led the development of Endourology for over a decade. This has included clinical trials in stone disease (TISU, PURE) and BPH (UK-ROPE), following earlier work on cannabinoids, intravesical Botox and sacral neuromodulation. Widely published and recognised for international contributions and live surgery, he is now the head of the research committee for the Societe Internationle d’Urologie based in Montreal. Offering comprehensive management of prostate disease, including minimally invasive options (Rezum, Urolift, PAE) as well as being a regional trainer for laser prostatectomy (HOLEP), he has developed an interest in Aquablation to offer a bespoke service for all aspects of BPH. Likewise offering comprehensive management of stone disease, this includes treatments including lithotripsy, ureteroscopy and percutaneous surgery, as well as medical treatment of metabolic stone disease. Having lectured and operated widely at home and abroad, he has been awarded Visiting Professorship at Cleveland Clinic (Ohio), Simpson-Smith Award (Duke University) and Edmondson Fellowship (University Southern California). Remaining committed to education both locally (educational trainer at Imperial College), nationally (FRCS(Urology) examiner) and internationally (SIU Academy), he is keen to optimise decision making in choice of operation, and optimise patient outcomes as a result.

Locations

The London Clinic London,

20 Devonshire PlaceLondon, W1G 6BWUnited Kingdom

All surgical treatments have inherent and associated side effects. Individual’s outcomes may depend on a number of factors, including but not limited to patient characteristics, disease characteristics and/or surgeon experience. The most common side effects are mild and transient and may include mild pain or difficulty when urinating, discomfort in the pelvis, blood in the urine, inability to empty the bladder or a frequent and/or urgent need to urinate, and bladder or urinary tract infection. Other risks include ejaculatory dysfunction and a low risk of injury to the urethra or rectum where the devices gain access to the body for treatment. Further, there may be other risks as in other urological surgery, such as anesthesia risk or the risk of infection, including the potential transmission of blood borne pathogens. For more information about potential side effects and risks associated with Aquablation therapy for Benign Prostatic Hyperplasia (BPH) treatment, speak with your urologist or surgeon. Prior to using our products, please review the Instructions for Use, Operator’s Manual or User Manual, as applicable, and any accompanying documentation for a complete listing of indications, contraindications, warnings, precautions and potential adverse events. No claim is made that the AquaBeam Robotic System will cure any medical condition, or entirely eliminate the diseased entity. Repeated treatment or alternative therapies may sometimes be required.

Rx Only